The 36-month beta value for HCAT is also noteworthy at 1.35. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 3 rating it as “overweight,” 5 rating it as “hold,” and 0 rating it as “sell.”
The public float for HCAT is 58.48M, and at present, short sellers hold a 4.37% of that float. The average trading volume of HCAT on December 27, 2024 was 498.60K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
HCAT) stock’s latest price update
Health Catalyst Inc (NASDAQ: HCAT) has seen a rise in its stock price by 2.75 in relation to its previous close of 6.90. However, the company has experienced a -2.48% decline in its stock price over the last five trading sessions. seekingalpha.com reported 2024-12-18 that Despite positive demand and fundamentals, I believe the market undervalues HCAT’s growth potential. Gross margin contraction is due to temporary headwinds, which should ease, leading to strong margin expansion. Risks include potential delays in growth acceleration and macroeconomic uncertainties.
HCAT’s Market Performance
Health Catalyst Inc (HCAT) has seen a -2.48% fall in stock performance for the week, with a -16.78% decline in the past month and a -15.49% plunge in the past quarter. The volatility ratio for the week is 5.16%, and the volatility levels for the past 30 days are at 5.90% for HCAT. The simple moving average for the past 20 days is -10.14% for HCAT’s stock, with a -2.11% simple moving average for the past 200 days.
Analysts’ Opinion of HCAT
Evercore ISI, on the other hand, stated in their research note that they expect to see HCAT reach a price target of $11. The rating they have provided for HCAT stocks is “Outperform” according to the report published on January 03rd, 2024.
Barclays gave a rating of “Overweight” to HCAT, setting the target price at $14 in the report published on January 03rd of the current year.
HCAT Trading at -11.63% from the 50-Day Moving Average
After a stumble in the market that brought HCAT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.86% of loss for the given period.
Volatility was left at 5.90%, however, over the last 30 days, the volatility rate increased by 5.16%, as shares sank -16.59% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.78% lower at present.
During the last 5 trading sessions, HCAT fell by -2.48%, which changed the moving average for the period of 200-days by -13.01% in comparison to the 20-day moving average, which settled at $7.89. In addition, Health Catalyst Inc saw -23.43% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HCAT starting from DUNCAN GALLAGHER, who proposed sale 4,500 shares at the price of $7.09 back on Dec 23 ’24. After this action, DUNCAN GALLAGHER now owns shares of Health Catalyst Inc, valued at $31,905 using the latest closing price.
Llewelyn Linda, the Chief People Officer of Health Catalyst Inc, sale 6,442 shares at $7.88 during a trade that took place back on Dec 16 ’24, which means that Llewelyn Linda is holding 98,702 shares at $50,794 based on the most recent closing price.
Stock Fundamentals for HCAT
Current profitability levels for the company are sitting at:
- -0.21 for the present operating margin
- 0.36 for the gross margin
The net margin for Health Catalyst Inc stands at -0.26. The total capital return value is set at -0.13. Equity return is now at value -21.46, with -10.37 for asset returns.
Based on Health Catalyst Inc (HCAT), the company’s capital structure generated 0.49 points at debt to capital in total, while cash flow to debt ratio is standing at -0.0. The debt to equity ratio resting at 0.97. The interest coverage ratio of the stock is -5.56.
Currently, EBITDA for the company is -66.46 million with net debt to EBITDA at -1.11. When we switch over and look at the enterprise to sales, we see a ratio of 1.55. The receivables turnover for the company is 5.85for trailing twelve months and the total asset turnover is 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.41.
Conclusion
In summary, Health Catalyst Inc (HCAT) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
